Application of CCL20 to evaluation of therapeutic effect of tumor chemotherapy and tumor therapy

A technology of use and medicine, applied in the field of oncology and diagnosis, can solve problems such as cancer treatment obstacles and limited chemotherapy effects

Active Publication Date: 2018-01-19
FUDAN UNIV SHANGHAI CANCER CENT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, in some patients, drug resistance problems that arise during chemotherapy greatly limit the efficacy of chemotherapy
However, the problem of resistance to taxane drugs, which are commonly used in clinical practice, has not been well resolved, which has brought great obstacles to cancer treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CCL20 to evaluation of therapeutic effect of tumor chemotherapy and tumor therapy
  • Application of CCL20 to evaluation of therapeutic effect of tumor chemotherapy and tumor therapy
  • Application of CCL20 to evaluation of therapeutic effect of tumor chemotherapy and tumor therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0179] Example 1. Treatment with taxane chemotherapy drugs significantly increases the expression level of CCL20 in tumor cells

[0180] 1.1 The mRNA expression level of CCL20 is significantly increased in triple-negative breast cancer cells

[0181] Human breast cancer cell lines SUM149, SUM159 and MDA-MB-231 were adherently cultured in 10cm culture dishes. When growing to 50% confluency, paclitaxel (SUM149, 2nM; SUM159, 10nM; MDA-MB-231, 13.46nM) or docetaxel (SUM149, 1nM; SUM159, 5nM; MDA-MB-231, 14.10nM) was used. nM) were processed, and a normal saline control group was set at the same time. During this period, fresh medium was replaced every other day for a total of 7 days of drug treatment. After the treatment, 0.05% EDTA-trypsin was used to digest (SUM149, 4min; SUM159, 2min; MDA-MB-231, 2min), and PBS containing 2% FBS was used to terminate the digestion. Centrifuge at 1200 rpm for 5 minutes at 4°C. Aspirate the supernatant, resuspend and wash with PBS. Centrifug...

Embodiment 2

[0201] Example 2. CCL20 is significantly highly expressed in paclitaxel-resistant strains of various cancers

[0202] Paclitaxel-resistant strain of human breast cancer cell line MDA-MB-231 (MDA-MB-231 / T) and its control cells (MDA-MB-231), paclitaxel-resistant strain of human ovarian cancer cell line A2780 (A2780 / T) T) and its control cells (A2780), the paclitaxel-resistant strain of the human colon cancer cell line HCT-8 (HCT-8 / T) and its control cells (HCT-8), cultured in a 10cm culture dish. When growing to 70% confluence, use 0.05% EDTA-trypsin digestion (MDA-MB-231, 2min) or 0.25% EDTA-trypsin digestion (A2780, HCT-8 are both 2min), PBS containing 2% FBS stop Digestion. Centrifuge at 1200 rpm for 5 minutes at 4°C. Aspirate the supernatant, resuspend and wash with PBS. Centrifuge again, discard the supernatant, collect the cells, extract RNA, and perform RT-PCR and real-time fluorescent quantitative PCR to detect the mRNA expression level of CCL20 in the cells of each ...

Embodiment 3

[0206] Example 3. CCL20 has a higher level in the serum of chemotherapy-resistant breast cancer patients

[0207] Blood was collected from breast cancer patients before and after neoadjuvant chemotherapy (two courses of chemotherapy, including paclitaxel or docetaxel in the chemotherapy regimen). Place in a centrifuge tube without any additives, place at room temperature for 20 minutes, centrifuge at 3000 rpm for 10 minutes, and absorb the supernatant. Serum was used to perform enzyme-linked immunosorbent assay (Raybio Company, Cat. No. ELH-MIP3a) to determine the level of CCL20 protein in serum.

[0208] The result is as Image 6 As shown in Table 6, there is no significant difference in CCL20 before and after chemotherapy in patients with complete pathological remission, while for patients with incomplete pathological remission, the level of CCL20 in blood after chemotherapy is significantly increased, which is about 1.7 times that before chemotherapy. Therefore, CCL20 has...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of CCL20 to the evaluation of the therapeutic effect of tumor chemotherapy and the tumor therapy. Particularly, the invention provides application of a CCL20 gene,mRNA, cDNA, a protein or a detection reagent thereof to preparing a diagnostic reagent or a kit for detecting the drug resistance of a taxane drug. The researches show that the CCL20 can serve as a marker to detect the drug resistance of the taxane drug, and/or can also serve as a target to weaken the drug resistance of the taxane drug. The invention further provides a CCL20-based method for weakening the drug resistance of the taxane drug and a drug composition.

Description

technical field [0001] The present invention relates to the fields of oncology and diagnostics. More specifically, the present invention relates to the application of CCL20 in tumor chemotherapy efficacy evaluation and tumor treatment. Background technique [0002] There are more than 7 million people suffering from cancer every year in the world, and about 5 million people are killed by cancer, accounting for about 10% of the total number of deaths. Cancer poses a severe challenge to human beings, and the prevention and treatment of cancer is still one of the three major problems in the field of human biomedicine. Now clinically, the methods of anti-cancer and cancer treatment mainly include surgical therapy, drug therapy (including chemical drugs, bioengineering drugs and radiopharmaceutical therapy) and physical therapy (such as utilizing the effects of light, heat, ultrasound, etc.). [0003] Chemotherapy is currently one of the most effective means of treating cancer....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574A61K45/06A61P35/00
Inventor 柳素玲陈为龙秦媛媛
Owner FUDAN UNIV SHANGHAI CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap